Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3020% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker Trauma and Extremities by Year
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Sales Growth YoY (Reported / Constant Currency, %) (%)
Stryker Trauma and Extremities: 13.1% in FY2025, up 0.5 pts from a year earlier.
Latest, FY2025
13.1%
Period ended Dec 31, 2025
Change on a year earlier
+0.5 pts
12.6% in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Where the FY2025 figure comes from
Reported in Stryker Form 8-K Supplemental Sales Schedules (100% USD; Reported = Constant Currency).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Stryker Trauma and Extremities (%), annual FY2015–FY2025 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/fran-trauma-us-rep
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.